Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56


Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group.

N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.


Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group.

Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.


Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles.

Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM.

ERJ Open Res. 2019 Jun 17;5(2). pii: 00082-2019. doi: 10.1183/23120541.00082-2019. eCollection 2019 Apr.


Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis.

Friedman D, Linnemann RW, Altstein LL, Georgiopoulos AM, Islam S, Bach KT, St John A, Fracchia MS, Neuringer I, Lapey A, Sicilian L, Moskowitz SM, Yonker LM.

Pediatr Pulmonol. 2019 Jul;54(7):984-992. doi: 10.1002/ppul.24311. Epub 2019 Mar 10.


Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa.

Han ML, Zhu Y, Creek DJ, Lin YW, Gutu AD, Hertzog P, Purcell T, Shen HH, Moskowitz SM, Velkov T, Li J.

mSystems. 2019 Jan 8;4(1). pii: e00149-18. doi: 10.1128/mSystems.00149-18. eCollection 2019 Jan-Feb.


Advance Care Planning Experiences and Preferences among People with Cystic Fibrosis.

Linnemann RW, Friedman D, Altstein LL, Islam S, Bach KT, Georgiopoulos AM, Moskowitz SM, Yonker LM.

J Palliat Med. 2019 Feb;22(2):138-144. doi: 10.1089/jpm.2018.0262. Epub 2018 Oct 18.


VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.


VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.


Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa.

Han ML, Zhu Y, Creek DJ, Lin YW, Anderson D, Shen HH, Tsuji B, Gutu AD, Moskowitz SM, Velkov T, Li J.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02656-17. doi: 10.1128/AAC.02656-17. Print 2018 Jun.


Polymyxin-Induced Lipid A Deacylation in Pseudomonas aeruginosa Perturbs Polymyxin Penetration and Confers High-Level Resistance.

Han ML, Velkov T, Zhu Y, Roberts KD, Le Brun AP, Chow SH, Gutu AD, Moskowitz SM, Shen HH, Li J.

ACS Chem Biol. 2018 Jan 19;13(1):121-130. doi: 10.1021/acschembio.7b00836. Epub 2017 Dec 11.


An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.

Koeva M, Gutu AD, Hebert W, Wager JD, Yonker LM, O'Toole GA, Ausubel FM, Moskowitz SM, Joseph-McCarthy D.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00987-17. doi: 10.1128/AAC.00987-17. Print 2017 Dec.


Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes.

Han ML, Shen HH, Hansford KA, Schneider EK, Sivanesan S, Roberts KD, Thompson PE, Le Brun AP, Zhu Y, Sani MA, Separovic F, Blaskovich MAT, Baker MA, Moskowitz SM, Cooper MA, Li J, Velkov T.

ACS Infect Dis. 2017 Aug 11;3(8):606-619. doi: 10.1021/acsinfecdis.7b00065. Epub 2017 Jul 11.


The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping.

Friedman D, Linnemann RW, Altstein LL, Islam S, Bach KT, Lamb C, Volpe J, Doolittle C, St John A, O'Malley PJ, Sawicki GS, Georgiopoulos AM, Yonker LM, Moskowitz SM.

J Cyst Fibros. 2018 Jan;17(1):71-77. doi: 10.1016/j.jcf.2017.02.011. Epub 2017 Mar 14.


Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control.

Meylan S, Porter CBM, Yang JH, Belenky P, Gutierrez A, Lobritz MA, Park J, Kim SH, Moskowitz SM, Collins JJ.

Cell Chem Biol. 2017 Feb 16;24(2):195-206. doi: 10.1016/j.chembiol.2016.12.015. Epub 2017 Jan 19.


Second Generation Modifiers of Colistin Resistance Show Enhanced Activity and Lower Inherent Toxicity.

Brackett CM, Furlani RE, Anderson RG, Krishnamurthy A, Melander RJ, Moskowitz SM, Ernst RK, Melander C.

Tetrahedron. 2016 Jun 23;72(25):3549-3553.


Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers.

Ong W, Nowak P, Cu Y, Schopf L, Bourassa J, Enlow E, Moskowitz SM, Chen H.

Pharm Res. 2016 Mar;33(3):563-72. doi: 10.1007/s11095-015-1808-x. Epub 2015 Oct 27.


Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.

Beringer PM, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME.

J Antimicrob Chemother. 2016 Jan;71(1):181-8. doi: 10.1093/jac/dkv301. Epub 2015 Oct 3.


CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 25-2015. An 8-Year-Old Girl with a Chest-Wall Mass and a Pleural Effusion.

Moskowitz SM, Shailam R, Mark EJ.

N Engl J Med. 2015 Aug 13;373(7):657-67. doi: 10.1056/NEJMcpc1400836. No abstract available.


Site-specific activity of the acyltransferases HtrB1 and HtrB2 in Pseudomonas aeruginosa lipid A biosynthesis.

Hittle LE, Powell DA, Jones JW, Tofigh M, Goodlett DR, Moskowitz SM, Ernst RK.

Pathog Dis. 2015 Nov;73(8):ftv053. doi: 10.1093/femspd/ftv053. Epub 2015 Jul 29.


Pseudomonas aeruginosa high-level resistance to polymyxins and other antimicrobial peptides requires cprA, a gene that is disrupted in the PAO1 strain.

Gutu AD, Rodgers NS, Park J, Moskowitz SM.

Antimicrob Agents Chemother. 2015 Sep;59(9):5377-87. doi: 10.1128/AAC.00904-15. Epub 2015 Jun 22.


Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers.

Linnemann RW, O'Malley PJ, Friedman D, Georgiopoulos AM, Buxton D, Altstein LL, Sicilian L, Lapey A, Sawicki GS, Moskowitz SM.

J Cyst Fibros. 2016 Jan;15(1):90-5. doi: 10.1016/j.jcf.2015.03.005. Epub 2015 Mar 25.


Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells.

Zemke AC, Shiva S, Burns JL, Moskowitz SM, Pilewski JM, Gladwin MT, Bomberger JM.

Free Radic Biol Med. 2014 Dec;77:307-16. doi: 10.1016/j.freeradbiomed.2014.08.011. Epub 2014 Sep 16.


Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.

Caceres SM, Malcolm KC, Taylor-Cousar JL, Nichols DP, Saavedra MT, Bratton DL, Moskowitz SM, Burns JL, Nick JA.

Antimicrob Agents Chemother. 2014 Nov;58(11):6851-60. doi: 10.1128/AAC.03514-14. Epub 2014 Sep 2.


Identification of inhibitors of PvdQ, an enzyme involved in the synthesis of the siderophore pyoverdine.

Wurst JM, Drake EJ, Theriault JR, Jewett IT, VerPlank L, Perez JR, Dandapani S, Palmer M, Moskowitz SM, Schreiber SL, Munoz B, Gulick AM.

ACS Chem Biol. 2014 Jul 18;9(7):1536-44. doi: 10.1021/cb5001586. Epub 2014 May 21.


Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation.

Yoo DG, Winn M, Pang L, Moskowitz SM, Malech HL, Leto TL, Rada B.

J Immunol. 2014 May 15;192(10):4728-38. doi: 10.4049/jimmunol.1301589. Epub 2014 Apr 16.


NET formation induced by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of myeloperoxidase-DNA and neutrophil elastase-DNA complexes.

Yoo DG, Floyd M, Winn M, Moskowitz SM, Rada B.

Immunol Lett. 2014 Aug;160(2):186-94. doi: 10.1016/j.imlet.2014.03.003. Epub 2014 Mar 23.


Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.

Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP.

Ann Am Thorac Soc. 2014 Mar;11(3):342-50. doi: 10.1513/AnnalsATS.201310-352OC.


A divergent Pseudomonas aeruginosa palmitoyltransferase essential for cystic fibrosis-specific lipid A.

Thaipisuttikul I, Hittle LE, Chandra R, Zangari D, Dixon CL, Garrett TA, Rasko DA, Dasgupta N, Moskowitz SM, Malmström L, Goodlett DR, Miller SI, Bishop RE, Ernst RK.

Mol Microbiol. 2014 Jan;91(1):158-74. doi: 10.1111/mmi.12451. Epub 2013 Nov 27.


Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.

Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Høiby N, Moskowitz SM.

Antimicrob Agents Chemother. 2013 May;57(5):2204-15. doi: 10.1128/AAC.02353-12. Epub 2013 Mar 4.


Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase.

Rada B, Jendrysik MA, Pang L, Hayes CP, Yoo DG, Park JJ, Moskowitz SM, Malech HL, Leto TL.

PLoS One. 2013;8(1):e54205. doi: 10.1371/journal.pone.0054205. Epub 2013 Jan 14.


PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients.

Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Høiby N.

Antimicrob Agents Chemother. 2012 Feb;56(2):1019-30. doi: 10.1128/AAC.05829-11. Epub 2011 Nov 21.


PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.

Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Høiby N, Moskowitz SM.

Antimicrob Agents Chemother. 2011 Dec;55(12):5761-9. doi: 10.1128/AAC.05391-11. Epub 2011 Oct 3.


Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.

Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA.

PLoS One. 2011;6(9):e23637. doi: 10.1371/journal.pone.0023637. Epub 2011 Sep 1.


Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.

Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL.

Pediatr Pulmonol. 2011 Feb;46(2):184-92. doi: 10.1002/ppul.21350. Epub 2010 Oct 20.


The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection.

Moskowitz SM, Ernst RK.

Subcell Biochem. 2010;53:241-53. doi: 10.1007/978-90-481-9078-2_11.


Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Moskowitz SM, Garber E, Chen Y, Clock SA, Tabibi S, Miller AK, Doctor M, Saiman L.

J Antimicrob Chemother. 2010 Jul;65(7):1416-23. doi: 10.1093/jac/dkq131. Epub 2010 Apr 29.


Mechanisms of bacterial virulence in pulmonary infections.

Moskowitz SM, Wiener-Kronish JP.

Curr Opin Crit Care. 2010 Feb;16(1):8-12. doi: 10.1097/MCC.0b013e3283354710. Review.


Pseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos.

Brannon MK, Davis JM, Mathias JR, Hall CJ, Emerson JC, Crosier PS, Huttenlocher A, Ramakrishnan L, Moskowitz SM.

Cell Microbiol. 2009 May;11(5):755-68. doi: 10.1111/j.1462-5822.2009.01288.x. Epub 2009 Jan 15.


Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR.

Genet Med. 2008 Dec;10(12):851-68. doi: 10.1097/GIM.0b013e31818e55a2. Review.


Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation.

Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, Oliver A.

J Bacteriol. 2008 Dec;190(24):7910-7. doi: 10.1128/JB.01147-08. Epub 2008 Oct 10.


Shifting patterns of inhaled antibiotic use in cystic fibrosis.

Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF).

Pediatr Pulmonol. 2008 Sep;43(9):874-81. doi: 10.1002/ppul.20873.


Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients.

Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N.

J Cyst Fibros. 2008 Sep;7(5):391-7. doi: 10.1016/j.jcf.2008.02.003. Epub 2008 Mar 20.


Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.

Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI.

J Infect Dis. 2007 Oct 1;196(7):1088-92. Epub 2007 Aug 22.


Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV.

Proc Natl Acad Sci U S A. 2006 May 30;103(22):8487-92. Epub 2006 May 10.


The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway.

Ernst RK, Adams KN, Moskowitz SM, Kraig GM, Kawasaki K, Stead CM, Trent MS, Miller SI.

J Bacteriol. 2006 Jan;188(1):191-201.


Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.

Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL.

J Antimicrob Chemother. 2005 Nov;56(5):879-86. Epub 2005 Sep 27.


Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Moskowitz SM, Gibson RL, Effmann EL.

Pediatr Radiol. 2005 Aug;35(8):739-57. Epub 2005 May 3. Review.


Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness.

Johnson LN, Han JY, Moskowitz SM, Burns JL, Qin X, Englund JA.

Pediatr Infect Dis J. 2004 Sep;23(9):881-2.


Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4.

Ernst RK, Hajjar AM, Tsai JH, Moskowitz SM, Wilson CB, Miller SI.

J Endotoxin Res. 2003;9(6):395-400.


Supplemental Content

Loading ...
Support Center